A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs LYC 30937 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Lycera
- 22 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2017 Time frame of primary endpoint has changed from 6 weeks to 46 weeks.
- 13 Dec 2016 Status changed from not yet recruiting to recruiting.